- Pace Life Sciences has completed a European Medicines Agency (EMA) Good Manufacturing Practice (GMP) inspection at its Lebanon, New Jersey facility as part of its EU GMP certificate renewal process. The inspection took place on October 13–14, 2026.
- The 40,000-square-foot facility provides analytical testing and development services, including stability testing, analytical method development and validation, microbiology testing, and container closure integrity testing.
Pace Life Sciences, a U.S.-based, FDA-registered GMP analytical testing laboratory and contract development and manufacturing organization (CDMO), has completed an EMA GMP inspection at its facility in Lebanon, New Jersey. Conducted on October 13 and 14, 2026, the inspection formed part of the site’s EU GMP certificate renewal process. A renewed certificate is expected to be issued.
The inspection assessed the facility’s quality systems and laboratory operations. Areas reviewed included stability programs, equipment qualification, sample receipt and management, employee training, corrective and preventive actions (CAPA), analytical procedures, data packages, and container closure integrity testing activities.
The 40,000-square-foot facility provides analytical testing and development support for pharmaceutical and biopharmaceutical companies. Its services include container closure integrity testing (CCIT), stability testing, analytical method development and validation, and microbiology testing.
“Our customers rely on defensible analytical data to bring safe, effective therapies to patients worldwide. This achievement reflects our team’s commitment to operational excellence and reinforces our ability to operate within rigorous international regulatory frameworks while delivering the reliable, high-quality data our clients depend on.”
Lou Forcellini, Vice President of Quality Assurance at Pace Life Sciences
Amanda Yoakum, Senior Director and Site Lead, said the successful inspection demonstrates the strength of the site’s quality systems and regulatory expertise. She added that the company remains focused on helping clients navigate regulatory requirements and advance pharmaceutical development and supply programs.
